A piece of news
He is taking over the position held since 2018 by Jordi Naval, now CEO of InProTher.
The Biocat Board of Trustees, chaired by President of the Government of Catalonia Pere Aragonès, has named Robert Fabregat the organization's new CEO. Fabregat is taking over the position left vacant when the previous CEO, Jordi Naval, left to head up Danish startup InProTher.
Robert Fabregat (Barcelona, 1980) has a degree in Chemistry and a PhD in Pharmacy from the University of Barcelona (UB), plus a master’s in Project Management from BES-La Salle. He was director general for Research and Innovation in Health for the Catalan Ministry of Health from 2019 to 2021, and department head for the same organization from 2018 to 2019. He has extensive experience managing national and international projects in the fields of healthcare and biomedicine, collaborating with various research centers, public bodies and companies. He has also been a professor at the UB.
“I am taking over management of Biocat with the deepest commitment to boosting the life sciences and healthcare innovation ecosystem in Catalonia, at this time that is key for the country's social and economic transformation,” highlights Robert Fabregat. “My main goals include: strengthening Biocat's role as an essential agent for boosting the country's research and innovation capacity, helping accelerate the transfer of medical technology and solutions to patients, and consolidating the BioRegion of Catalonia as one of the most important healthcare innovation hubs in Europe.”
Ignasi Biosca, vice-president of the Biocat Board of Trustees, thanked Jordi Naval for his work leading the organization and welcomed the new CEO, wishing him much success.